Picture of virus

Open Access research that helps to deliver "better medicines"...

Strathprints makes available scholarly Open Access content by the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), a major research centre in Scotland and amongst the UK's top schools of pharmacy.

Research at SIPBS includes the "New medicines", "Better medicines" and "Better use of medicines" research groups. Together their research explores multidisciplinary approaches to improve understanding of fundamental bioscience and identify novel therapeutic targets with the aim of developing therapeutic interventions, investigation of the development and manufacture of drug substances and products, and harnessing Scotland's rich health informatics datasets to inform stratified medicine approaches and investigate the impact of public health interventions.

Explore Open Access research by SIPBS. Or explore all of Strathclyde's Open Access research...

Survival and re-operation rates after neurosurgical procedures in scotland: Implications for targeted surveillance of sub-clinical variant Creutzfeldt-Jakob disease

Bird, S.M. and Merrall, Elizabeth L.C. and Ward, Hester J.T. and Will, Robert G. (2009) Survival and re-operation rates after neurosurgical procedures in scotland: Implications for targeted surveillance of sub-clinical variant Creutzfeldt-Jakob disease. Neuroepidemiology, 33 (1). pp. 1-11. ISSN 0251-5350

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

Background/Aim: To assess the feasibility of post-mortem surveillance for subclinical variant Creutzfeldt-Jakob disease (vCJD) at least 5 years after neurosurgical procedures. Methods: Using Scottish record linkage, we estimated 5-year survival and re-operation rates after 4 neurosurgical procedures performed during 1993-2001 and identified as high or medium risk for transmitting vCJD: [B] drainage of extra-or subdural haematoma, [E] primary or revisional decompression operations and [H] creation of other ventricular shunts were classified as high risk; [C] operations on cerebral aneurysm (clipping) were classified as medium risk. Results: Fatality rate at 1 year depended strongly on procedure, weakly or not at all on sex and era, and increased with age. Procedure rates differed by sex. The rate of subsequent neurosurgical operations was highest for procedure [H] (sole: 21%; multiple: 28%). Conclusion: Each year, the UK has a new cohort of some 5,000 5-year survivors after a high- or medium-risk neurosurgical procedure, whose subsequent annual mortality is at least 3%. Even if half the surviving 5-year survivors of neurosurgery since 1996 gave consent-in-life for vCJD-informative testing at post-mortem, there would be too few relevant post-mortems in 2008-2010 (around 1,600) for 'nil detections' to exclude a 1 in 1,000 subclinical vCJD rate. Autopsy surveillance beyond 2010, or among 5-year survivors of non-neurosurgical at-risk operations, would be needed.